<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538625</url>
  </required_header>
  <id_info>
    <org_study_id>NP 303-102</org_study_id>
    <nct_id>NCT04538625</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy</brief_title>
  <acronym>OnTARGET</acronym>
  <official_title>A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Napo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Napo Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 24-week, (two 12-week stages), randomized, placebo-controlled, double-blind study to&#xD;
      evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult&#xD;
      patients with solid tumors treated with targeted cancer therapy-containing treatment&#xD;
      regimens. Diarrhea grading will be done according to the National Cancer Institute Common&#xD;
      Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.&#xD;
&#xD;
      Patients will be randomized 1:1 to placebo or crofelemer and will be stratified by the type&#xD;
      of targeted cancer therapy and the tumor type. Placebo and/or crofelemer will be dispensed at&#xD;
      Visit 1/Day 1 with the concurrent start of the targeted cancer therapy regimen. The initial&#xD;
      Stage I double-blind placebo-controlled primary treatment phase will occur over a 12-week&#xD;
      period to accommodate approximately 3 cycle chemotherapy cancer treatment dosing-cycles. The&#xD;
      Primary and Secondary Endpoints will be analyzed after the last patient last visit (LPLV) of&#xD;
      Stage I.&#xD;
&#xD;
      After completing the Stage I double-blind, placebo-controlled primary treatment phase, the&#xD;
      subjects will have the option to remain on their assigned treatment arm and reconsented to&#xD;
      enter into the Stage II extension phase. Reconsent will be required to enter into Stage II.&#xD;
      For subjects who do not reconsent, visit 5 will be the last study visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, placebo controlled, double blind study to evaluate the safety and efficacy of&#xD;
      crofelemer in providing prophylaxis of diarrhea in adult patients with solid tumors receiving&#xD;
      targeted cancer therapy containing regimens. Diarrhea grading will be done according to the&#xD;
      National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE Ver. 5.0).&#xD;
&#xD;
      Randomization will be at a 1:1 ratio with subjects randomized either to crofelemer 125 mg&#xD;
      delayed-release tablets or matching placebo tablets administered orally twice daily with or&#xD;
      without food. Randomization will be stratified by the type of targeted cancer therapy and by&#xD;
      tumor type. Placebo and crofelemer treatment will be initiated concomitantly with the&#xD;
      administration of targeted cancer therapy-containing regimens.&#xD;
&#xD;
      The Stage I double-blind placebo-controlled primary treatment phase will be the first 12-week&#xD;
      period to accommodate targeted cancer therapy with approximately three (3) cycle chemotherapy&#xD;
      regimens (if needed) over the inclusive 12-week period after initiation of crofelemer or&#xD;
      placebo treatment in Stage I.&#xD;
&#xD;
      After completing the Stage I treatment phase (12 weeks), and after the LPLV of the primary&#xD;
      Stage I treatment phase, the primary and secondary endpoints will be analyzed. The subjects&#xD;
      will have the option to remain on their assigned treatment arm and reconsented to enter into&#xD;
      the Stage II extension phase. Reconsent will be required to enter into Stage II. For subjects&#xD;
      who do not reconsent, Visit 5 will be the last study visit. Subjects who enter into the Stage&#xD;
      II extension phase will continue on their originally assigned study treatment commenced at&#xD;
      the beginning of Stage I.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, placebo controlled, double blind study to evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult patients with solid tumors receiving targeted cancer therapy containing regimens. Diarrhea grading will be done according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE Ver. 5.0).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Number of Loose/watery Stools</measure>
    <time_frame>For the entire 12-week double-blind placebo-controlled treatment period (The Stage 1 Primary Treatment Phase).</time_frame>
    <description>The frequency of diarrhea as measured by the average number of loose/watery stools per week will be evaluated as a continuous endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Durable, Clinical Responders</measure>
    <time_frame>Initial 12-week (Stage 1) period of the study.</time_frame>
    <description>Proportion of &quot;durable responders&quot; defined as the proportion of subjects with ≤7 loose and/or watery bowel movements per week for at least 50% of the time over the Stage 1 double-blind placebo-controlled primary treatment period (Stage 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Number of Weekly Loose/Watery Stools</measure>
    <time_frame>Initial 12-week (Stage 1) period of the study.</time_frame>
    <description>Maximum number of weekly unformed (loose and/or watery) bowel movements from Week 1 through end of Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Incontinence</measure>
    <time_frame>Initial 12-week (Stage 1) period of the study.</time_frame>
    <description>Mean number of fecal incontinence episodes from Week 1 through end of Week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Cancer Therapy-Related Diarrhea</condition>
  <condition>Chemotherapy-related Diarrhea</condition>
  <condition>Adult Solid Tumor</condition>
  <condition>Prophylaxis of Diarrhea</condition>
  <condition>Symptomatic Relief of Diarrhea</condition>
  <condition>Targeted Therapy-related Diarrhea</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the placebo arm, will receive oral doses of matching placebo tablets twice daily with or without food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crofelemer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the crofelemer arm, will receive oral doses of crofelemer 125mg delayed-release tablets twice daily with or without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crofelemer 125 MG [Mytesi]</intervention_name>
    <description>Randomized, Double-blind, Placebo-controlled, two arm trial</description>
    <arm_group_label>Crofelemer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients to receive targeted cancer therapy drugs that have a reported an all grade&#xD;
             diarrhea incidence of 50% or higher (e.g., tyrosine kinase inhibitors, cdk inhibitors,&#xD;
             anti-EGFR, etc., for treatment of solid tumors.&#xD;
&#xD;
             2. Patients able to provide written informed consent.&#xD;
&#xD;
             3. Men and women ≥ 18 years of age.&#xD;
&#xD;
             4. Pathologically and/or radiologically confirmed diagnosis of solid tumors scheduled&#xD;
             to receive targeted cancer therapy.&#xD;
&#xD;
             5. Patients eligible to receive targeted cancer therapy per NCCN (National&#xD;
             Comprehensive Cancer Network) guidelines and/or standard-of-care practice, with or&#xD;
             without cycle chemotherapy.&#xD;
&#xD;
             6. Patient can receive concomitant cycle [standard] chemotherapy agents together with&#xD;
             their targeted cancer therapy treatment regimens.&#xD;
&#xD;
             7. ECOG (Eastern Cooperative Oncology Group) performance status 0-2 and expected to&#xD;
             survive a 12-week course of targeted therapy with or without chemotherapy&#xD;
&#xD;
             8. Negative urine pregnancy test at time of informed consent for women of childbearing&#xD;
             potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients receiving any type of immunotherapy including but not limited to immune&#xD;
             checkpoint inhibitors that inhibit negative regulatory components of immune response&#xD;
             such as cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and the programmed cell&#xD;
             death protein-1 and its ligand (PD1/ PDL1) and IL-2 cancer immunotherapy.&#xD;
&#xD;
             2. Any cancer therapy for which antidiarrheal (antimotility) medications in the&#xD;
             prophylaxis setting is mandatory, including but not limited to patients receiving&#xD;
             neratinib and irinotecan.&#xD;
&#xD;
             3. Ongoing irritable bowel syndrome (IBS) or colitis (including but not limited to&#xD;
             ulcerative colitis, Crohn's disease, microscopic colitis, etc.).&#xD;
&#xD;
             4. Ongoing diarrhea and/or diarrheal episodes within the previous 7 days prior to&#xD;
             randomization into the study.&#xD;
&#xD;
             5. Laxative use within 7 days prior to randomization or a history of constipation&#xD;
             requiring the use of laxatives for more than ≥ 30 consecutive days.&#xD;
&#xD;
             6. Inadequate organ function, which may include, but is not limited to, the following&#xD;
             laboratory results within 28 days prior to signing consent: Total bilirubin &gt; upper&#xD;
             limit of normal (ULN), AST (SGOT) and ALT (SPGT) &gt; 2.5 ULN (unless the participant has&#xD;
             documented Gilbert's syndrome, hepatocellular carcinoma or hepatic metastases), serum&#xD;
             creatinine &gt; 2.0 mg/dL or 177 μmol/L.&#xD;
&#xD;
               1. NOTE: Investigator discretion will determine continued eligibility after&#xD;
                  randomization occurs, in the event the liver function test results are greater&#xD;
                  than (&gt;) the proposed upper limit of normal.&#xD;
&#xD;
                  7. Use of other investigational drugs within 4 weeks of signed informed consent&#xD;
                  or foreseen use during the study.&#xD;
&#xD;
                  8. Use of antibiotics within the past 7 days (up to 2 prophylactic doses of&#xD;
                  antibiotic for procedures, including but not limited to port placement, is&#xD;
                  permitted) prior to randomization.&#xD;
&#xD;
                  9. Total colectomy and/or any type of gastrointestinal ostomy.&#xD;
&#xD;
                  10. Major abdominal or pelvic surgery within the past 3 months.&#xD;
&#xD;
                  11. Previous (within 1 month) or planned abdominal and/or pelvic radiation.&#xD;
&#xD;
                  12. Fecal incontinence from ongoing radiation-induced diarrhea or constipation&#xD;
&#xD;
                  13. Active systemic infection requiring ongoing intervention, including but not&#xD;
                  limited to oral and intravenous antibiotics, anti-fungals, anti-parasitics, and&#xD;
                  anti-viral drugs.&#xD;
&#xD;
                  14. Inability to comply with study requirements as judged by the Investigator.&#xD;
&#xD;
                  15. Pregnant and/or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Okhuysen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pravin Chaturvedi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Napo Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Garufis, MA S</last_name>
    <phone>+1 (714) 210-6648</phone>
    <email>Lauren.Garufis@Integrium.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gina B Franklin, RN MSN</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92882</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Tieng</last_name>
      <phone>562-693-4477</phone>
      <email>stieng@icrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Gilmore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Tieng</last_name>
      <phone>562-693-4477</phone>
      <email>stieng@icrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Paul LaPorte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCL Health Research Institute</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Franklin, MS</last_name>
      <phone>303-318-3413</phone>
      <email>alan.franklin@scl.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BRCR Global</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Hilewsky</last_name>
      <phone>561-447-0614</phone>
      <email>Barbara.h@brcrglobal.com</email>
    </contact>
    <investigator>
      <last_name>Amin Harshad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunny Raiker, MD</last_name>
      <phone>727-835-3261</phone>
      <email>sunny.raiker@ariclinical.com</email>
    </contact>
    <investigator>
      <last_name>Anilkumar Raiker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tajuana Richardson</last_name>
      <phone>240-482-0526</phone>
      <email>tajuana.Richardson@aoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Conyers</last_name>
      <phone>402-354-5162</phone>
      <email>Brianna.conyers@nmhs.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Dorius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates dba New York Cancer and Blood Specialists</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Brady, LPN</last_name>
      <phone>631-675-5146</phone>
      <email>lbrady@nycancer.com</email>
    </contact>
    <investigator>
      <last_name>Richard Zuniga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Rich</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>207</phone_ext>
      <email>arich@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic Research</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>India Holmes</last_name>
      <phone>981-683-0055</phone>
      <email>iholmes@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Vidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Fernandes</last_name>
      <phone>713-582-1537</phone>
      <email>kefernan@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Pablo Okhuysen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Fisher</last_name>
      <phone>571-472-4724</phone>
      <email>Carrie.Fisher@inova.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen Harnden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Wahinekapu</last_name>
      <phone>713-582-1537</phone>
      <email>dwakinekapu@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Anuradha Belur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hirsh V, Blais N, Burkes R, Verma S, Croitoru K. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol. 2014 Dec;21(6):329-36. doi: 10.3747/co.21.2241.</citation>
    <PMID>25489260</PMID>
  </reference>
  <reference>
    <citation>Davila M, Bresalier RS. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol. 2008 Dec;5(12):682-96. doi: 10.1038/ncpgasthep1277. Epub 2008 Oct 21. Review.</citation>
    <PMID>18941434</PMID>
  </reference>
  <reference>
    <citation>Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer. 2006 Sep;14(9):890-900. Epub 2006 Apr 8. Review.</citation>
    <PMID>16604351</PMID>
  </reference>
  <reference>
    <citation>Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010 Jan;2(1):51-63. doi: 10.1177/1758834009355164.</citation>
    <PMID>21789126</PMID>
  </reference>
  <reference>
    <citation>Engelking C, Rutledge DN, Ippoliti C, Neumann J, Hogan CM. Cancer-related diarrhea: a neglected cause of cancer-related symptom distress. Oncol Nurs Forum. 1998 Jun;25(5):859-60.</citation>
    <PMID>9644701</PMID>
  </reference>
  <reference>
    <citation>Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15;22(14):2918-26.</citation>
    <PMID>15254061</PMID>
  </reference>
  <reference>
    <citation>Di Fiore F, Van Cutsem E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract Res Clin Gastroenterol. 2009;23(1):113-24. doi: 10.1016/j.bpg.2008.11.016. Review.</citation>
    <PMID>19258191</PMID>
  </reference>
  <reference>
    <citation>Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics. 2013 Sep;31(9):753-66. doi: 10.1007/s40273-013-0081-2. Review.</citation>
    <PMID>23963867</PMID>
  </reference>
  <reference>
    <citation>Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care. 2013 Jun;7(2):162-7. doi: 10.1097/SPC.0b013e32835ec861. Review.</citation>
    <PMID>23399616</PMID>
  </reference>
  <reference>
    <citation>Crutchley RD, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010 May;44(5):878-84. doi: 10.1345/aph.1M658. Epub 2010 Apr 13. Review.</citation>
    <PMID>20388859</PMID>
  </reference>
  <reference>
    <citation>Cottreau J, Tucker A, Crutchley R, Garey KW. Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol. 2012 Feb;6(1):17-23. doi: 10.1586/egh.11.87. Review.</citation>
    <PMID>22149578</PMID>
  </reference>
  <reference>
    <citation>Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010 Jan;77(1):69-78. doi: 10.1124/mol.109.061051. Epub 2009 Oct 6.</citation>
    <PMID>19808995</PMID>
  </reference>
  <reference>
    <citation>Holodniy M, Koch J, Mistal M, Schmidt JM, Khandwala A, Pennington JE, Porter SB. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol. 1999 Nov;94(11):3267-73.</citation>
    <PMID>10566728</PMID>
  </reference>
  <reference>
    <citation>DiCesare D, DuPont HL, Mathewson JJ, Ashley D, Martinez-Sandoval F, Pennington JE, Porter SB. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol. 2002 Oct;97(10):2585-8.</citation>
    <PMID>12385443</PMID>
  </reference>
  <reference>
    <citation>Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion. 2008;78(4):180-6. doi: 10.1159/000185719. Epub 2008 Dec 18.</citation>
    <PMID>19092244</PMID>
  </reference>
  <reference>
    <citation>Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, Garassino M, Ripamonti CI. Targeted therapy-induced diarrhea: A review of the literature. Crit Rev Oncol Hematol. 2014 May;90(2):165-79. doi: 10.1016/j.critrevonc.2013.11.008. Epub 2013 Dec 5. Review.</citation>
    <PMID>24373918</PMID>
  </reference>
  <reference>
    <citation>Macarthur RD, Hawkins TN, Brown SJ, Lamarca A, Clay PG, Barrett AC, Bortey E, Paterson C, Golden PL, Forbes WP. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013 Nov-Dec;14(6):261-73. doi: 10.1310/hct1406-261.</citation>
    <PMID>24334179</PMID>
  </reference>
  <reference>
    <citation>Nee J, Salley K, Ludwig AG, Sommers T, Ballou S, Takazawa E, Duehren S, Singh P, Iturrino J, Katon J, Lee HN, Rangan V, Lembo AJ. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2019 Dec;10(12):e00110. doi: 10.14309/ctg.0000000000000110.</citation>
    <PMID>31800542</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

